🚨 New paper alert 🚨
- vor 5 Stunden
- 1 Min. Lesezeit
Our latest paper is now published in Cancer Discovery, exploring new strategies to overcome CAR T cell dysfunction.
We developed an integrated chronic in vivo and in vitro screening platform to uncover regulators of dysfunctional CAR T-cell states and identified NFIL3 as a key driver.
NFIL3 disruption improved CAR T-cell persistence, cytokine production, and antitumor efficacy across hematologic and solid tumor models.
This study presents new strategies to promote durable CAR T-cell responses.
Read the paper here: https://doi.org/10.1158/2159-8290.CD-25-1524
We thank our close collaborators at the Columbia Initiative in Cell Engineering and Therapy (CICET), all funding parties and the iFIT Cluster of Excellence for their support! 🎉
